Custom slow-coagulation transscleral cyclophotocoagulation: a novel cyclophotocoagulation technique for refractory...

Glaucoma is one of the leading causes of irreversible blindness worldwide. When topical hypotensive agents or laser trabeculoplasty fail to adequately control the disease, escalation of therapy becomes necessary, with transscleral cyclophotocoagulation being one of the available options. Several variations of transscleral cyclophotocoagulation exist, including traditional continuous wave, MicroPulse, and slow-coagulation techniques. We propose a novel variation - custom slow-coagulation transscleral cyclophotocoagulation - which combines elements of both continuous wave and slow-coagulation approaches. This study aimed to evaluate the outcomes of this technique in patients with refractory glaucoma.

This retrospective, interventional study included 104 eyes of 83 patients with refractory glaucoma who underwent custom slow-coagulation transscleral cyclophotocoagulation. Changes in intraocular pressure, visual acuity, the number of glaucoma medications, and postoperative complications were analyzed. A paired t test was used to compare changes in intraocular pressure and visual acuity, while the Wilcoxon signed-rank test was applied to categorical variables. Success rates following custom slow-coagulation transscleral cyclophotocoagulation were estimated using Kaplan-Meier survival analysis.

Mean intraocular pressure decreased significantly from 38.9 ± 15.8 mmHg at baseline to 16.3 ± 9.9 mmHg at Month 12 (p<0.001). The mean number of glaucoma medications also decreased significantly from 3.6 ± 0.6 to 1.8 ± 1.4 (p<0.001). No significant reduction in mean visual acuity was observed during follow-up.

Custom slow-coagulation transscleral cyclophotocoagulation effectively reduced baseline intraocular pressure and the number of glaucoma medications, with a low rate of complications and no decline in visual acuity over a 12-month follow-up period. This novel technique demonstrated a high safety profile in a Hispanic population and represents a low-cost, minimally invasive procedure with rapid recovery and promising efficacy in intraocular pressure control.